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Abstract
Background:  Acute pancreatitis is a common complication of endoscopic retrograde
cholangiopancreatography and the benefit of its pharmacological treatment is unclear. Although
prophylactic use of gabexate for the reduction of pancreatic injury after ERCP has been evaluated,
the discrepancy about gabexate's beneficial effect on pancreatic injury still exists. This study aimed
to evaluate the effectiveness and safety of gabexate in the prophylaxis of post-endoscopic
retrograde cholangiopancreatography pancreatitis (PEP).
Methods: We employed the method recommended by the Cochrane Collaboration to perform
a meta-analysis of randomized controlled trials (RCTs) of gabexate in the prevention of post-ERCP
pancreatitis (PEP) including three RCTs conducted in Italy and one in China.
Results: All of the four RCTs were of high quality. When the RCTs were analyzed, odds ratios
(OR) for gabexate mesilate were 0.67 [95% CI (0.31~1.47), p = 0.32] for PEP, 3.78 [95% CI
(0.62~22.98), p = 0.15] for severe PEP, 0.68 [95% CI (0.19~2.43), p = 0.56] for the case-fatality of
PEP, 0.88 [95% CI (0.72~1.07), p = 0.20] for post-ERCP hyperamylasemia, 0.69 [95% CI
(0.39~1.21), p = 0.19] for post-ERCP abdominal pain, thus indicating no beneficial effects of
gabexate on acute pancreatitis, the death rate of PEP, hyperamylasemia and abdominal pain. No
evidence of publication bias was found.
Conclusion:  Gabexate mesilate can not prevent the pancreatic injury after ERCP. It is not
recommended for the use of gabexate mesilate in the prophylaxis of PEP.
Background
ERCP is one of the important procedures for the diagnosis
and treatment of several biliary and pancreatic conditions.
However, ERCP can also cause acute pancreatitis and
result in significant morbidity and mortality [1,2].
Depending on the definition, it has been reported that the
incidence of post-ERCP pancreatitis (PEP) was 1% to 40%
of cases, whereas post-operative hyperamylasemia can be
up to 70% of cases [3]. Although most cases of PEP were
mild, there were still 10% of cases developing to severe
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pancreatitis, which could result in prolonged stay in the
hospitals and increase the risk to patients' life.
Since the activation of proteases is one of the forms of the
recognized PEP pathogenesis, agents that inhibit proteo-
lytic activity were examined in several studies. Although a
recent report indicated prophylactic treatment with gabex-
ate could reduce pancreatic injury after ERCP [4], other
studies reported marginal beneficial effect of gabexate on
PEP [5,6]. The contradictory results of gabexate mesilate
in the prophylaxis of PEP can only be resolved from large
prospective randomized clinical trials (RCTs). However, a
meta-analysis of all available RCTs will provide useful
information for the use of gabexate mesilate in the proph-
ylaxis of PEP. Since gabexate is used prophylactically to
prevent pancreatic injury after ERCP in China, we
included a RCT [7] conducted in Chinese population in
current meta-analysis.
Methods
Selection criteria
We searched different databases, which included the
Cochrane Controlled Trials Register on The Cochrane
Library Issue 2, 2006, MEDLINE (January, 1966 – June,
2006), EMBASE.com (January, 1966 – June, 2006) and
the China Biological Medicine Datadase (CBMdisc) (Jan-
uary, 1978 – June, 2006) by the terms of pancreatitis,
ERCP, prevent*, gabexate, PEP. The reference lists of perti-
nent reviews and retrieved articles had been also checked
for additional studies identification.
In the meta-analysis, the following inclusive selection cri-
teria were set and reviewed by two independent investiga-
tors: (1) each trial should be a prospective randomized
controlled clinical trial, (2) the age of patient population
should be over 18 years, (3) the patients were scheduled
to undergo ERCP and/or endoscopic sphincterotomy, (4)
randomized comparisons of gabexate versus placebo or
blank control should be included regardless of the initial
time of treatment, treatment duration, dose and adminis-
tration route of the drug, (5) co-interventions (including
treatment of complications) were allowed if administered
equally to all intervention groups. The following exclusive
selection criteria were set: (1) quasi-randomized trials and
non-randomized studies, (2) active acute pancreatitis,
chronic pancreatitis, pancreatic cancer, or cancer of the
papilla of Vater, (3) difference of co-interventions
between intervention arms, (4) the raw data was not com-
pleted, (5) repetitive reports (if more than one version of
the same study was retrieved, only the most recent was
used).
A total of 30 clinical trials and reports has been identified
and only four trials [4,7-9] were qualified by our selection
criteria (Figure 1). The studies were independently evalu-
ated by two of us with five outcomes, which included
three primary outcomes (PEP, severe PEP and the case-
fatality ratio of PEP) and two secondary outcomes (post-
ERCP hyperamylasemia and abdominal pain). Discrepan-
cies in the evaluation of some of the studies were resolved
through discussion between the reviewers. The main fea-
tures of the trials included in the meta-analysis are shown
in Table 1.
Assessment of study quality
Quality of included reports was scored using the Jadad
composite scale [10], which assesses the descriptions of
randomization, blinding, and dropouts (withdrawals) in
the report [11]. The quality scale ranges from 0 to 5 points
with a low-quality report of score 2 or less and a high-
quality report of score at least 3 [12]. The quality score of
the four RCTs were shown in Table 2.
Statistical analysis
The meta-analysis was carried out by a biostatistician
(X.Y.) according to the Cochrane Reviewers' Handbook
recommended by The Cochrane Collaboration. Pooled
odds ratio (OR) was calculated using the general inverse
variance (IV) fixed-effect model. The heterogeneity
between studies was examined by DL Q statistic [13]. If
results were heterogeneous (p < 0.05), a random-effects
model was employed using the DerSimonian and Laird
(DL) methods. Pooled OR was presented as standard
plots with 95 percent confidence intervals (CI). Begg and
Mazumdar's proposed adjusted rank correlation test [14]
and Egger's linear regression approach [15] were used to
measure publication bias, which was shown as a funnel
plot. Sensitivity-analysis was also performed to assess the
reliability of meta-analysis. The statistical package Rev-
Man version 4.2 (provided by The Cochrane Collabora-
tion, Oxford, England) was used for the statistical
analysis.
Results
Primary outcome
In this report, we considered PEP as the primary outcome
which was divided into general PEP and severe PEP. The
report of general PEP was noticed in all four RCTs [4,7-9].
These trials included 1783 patients with 104 patients suf-
fering from PEP. Among PEP-suffering patients, 46
patients were treated with gabexate whereas 58 patients
were treated with placebo. There was a significant hetero-
geneity among these studies (Q = 9.26, 3 degrees of free-
dom, p = 0.03). However, analysis by random-effects
model indicated a DL random-effect pooled OR = 0.67
[(95 percent CI 0.31 to 1.47); p = 0.32] with no significant
association between the use of gabexate and the reduction
of PEP (Figure 2).BMC Gastroenterology 2007, 7:6 http://www.biomedcentral.com/1471-230X/7/6
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Severe PEP was reported in two trials [8,9]. These two tri-
als included 1172 patients with 6 patients suffering from
severe PEP (5 in gabexate treatment group and 1 in the
control group). The Q test of heterogeneity between stud-
ies was not significant (Q = 1.24, 1 degree of freedom, p =
0.27). The meta-analysis did not indicate association
between gabexate use and reduction of severe PEP [IV
fixed-effect pooled OR 3.78 (95 percent CI 0.62 to 22.98);
p = 0.15] (Figure 2).
In addition, case-fatality ratio of PEP in these trials was
extracted with report of case-fatality ratio in two trials
[4,7]. The two trials included 1194 patients with 10
deaths in gabexate group and 6 in the control group. The
Q test of heterogeneity of effect sizes was not significant
(Q = 0.09, 1 degree of freedom, p = 0.76). Moreover, there
was no significant association between the use of gabexate
and the reduction of case-fatality ratio of PEP [IV fixed-
effect pooled OR 0.68 (95 percent CI 0.19 to 2.43); p =
0.56] (Figure 2).
Secondary outcome
Both post-ERCP hyperamylasemia and abdominal pain
were considered as secondary outcome in the report. For
Identification of eligible randomized controlled trials from different medicine databases Figure 1
Identification of eligible randomized controlled trials from different medicine databases.
MEDLINE (1966June, 2006)
EMBASE.com (1966June, 2006)
CBMdisc (January, 1978June, 2006)
Cochrane Controlled Trial Register (Issue 2, 2006)
Potentially appropriate trials to be
included in meta-analysis (n=25)
Five additional studies were identified
from the reference lists of pertinent
reviews and retrieved articles
n=30
Randomized controlled trials
included in meta-analysis
(n=4)
Excluded (n=26)
Reviews or editorials (n=9)
Meta-analysis (n=2)
Repeat publication (n=2)
Abstract or data insufficient (n=5)
Incorrect randomization (n=1)
Placebo group lacking (n=1)
Others (n=6)B
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Table 1: Randomized controlled trials on the use of gabexate for the prevention of pancreatic injury after ERCP
Reference Setting Sample size Patient inclusion criteria Interventions Outcomes Allocation 
concealment
[4] Italy multicentre 418 Patients over 18 years of age who were 
scheduled to undergo ERCP and, when 
indicated, endoscopic sphincterotomy
Gabexate 1 g given by intravenous infusion 
starting 30 to 90 minutes before 
endoscopy and continuing for 12 hours 
afterward
The incidence of PEP, post-ERCP 
hyperamylasemia, post-ERCP abdominal 
pain, case-fatality ratio of PEP
Adequate
[9] Italy multicentre 396 Patients over 18 years of age who were 
scheduled to undergo ERCP and, when 
indicated, endoscopic sphincterotomy with 
one of the following "high risk" factors:
1) a non-dilated (< 8 mm in diameter) bile 
duct on pre-ERCP US
2) a history of gallstone-induced or post-
ERCP pancreatitis
3) suspected sphincter of Oddi dysfunction
Gabexate 500 mg given by intravenous 
infusion starting 30 minutes before 
endoscopy and continuing for 2 hours 
afterward
The incidence of PEP, severe PEP, post-
ERCP hyperamylasemia, post-ERCP 
abdominal pain
Adequate
[8] Italy multicentre 776 Patients over 18 years of age who were 
scheduled to undergo ERCP and, when 
indicated, endoscopic sphincterotomy
Gabexate 500 mg given by intravenous 
infusion starting 30 before endoscopy and 
continuing for 6 hours afterward
The incidence of PEP, severe PEP, post-
ERCP hyperamylasemia, post-ERCP 
abdominal pain, case-fatality ratio of PEP
Adequate
[7] China single centre 193 Patients over 18 years of age who were 
scheduled to undergo ERCP and, when 
indicated, endoscopic sphincterotomy
Gabexate 300 mg given by intravenous 
infusion starting 30 before endoscopy and 
continuing for 4.5 hours afterward
The incidence of PEP, post-ERCP 
hyperamylasemia, post-ERCP abdominal 
pain
Adequate
Table 2: Jadad quality score of randomized controlled trials included in the meta-analysis
Reference Randomization Blinding Withdrawals and dropouts Jadad score
[4] Centralized randomization schedule Double blinding Clearly reported 5
[9] Computer-generated list Double blinding Clearly reported 5
[8] Computer-generated list Double blinding Clearly reported 5
[7] Computer-generated randomized set of numbers Double blinding Clearly reported 5BMC Gastroenterology 2007, 7:6 http://www.biomedcentral.com/1471-230X/7/6
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post-ERCP hyperamylasemia, data were derived from all
four RCTs [4,7-9]. These trials included 1783 patients
with 700 patients suffering from post-ERCP hyperamy-
lasemia. Among these patients, 335 patients were treated
with gabexate and 365 patients with placebo. The Q test
of heterogeneity of effect sizes was not significant (Q =
1.40, 3 degrees of freedom, p = 0.71). Although the post-
ERCP hyperamylasemia was noted in 37.9% of patients
with gabexate and in 40.6% of control patients, the results
of the meta-analysis indicated no significant association
between the use of gabexate and reduction of post-ERCP
hyperamylasemia [IV fixed-effect pooled OR 0.88 (95 per-
cent CI 0.72 to 1.07); p = 0.20] (Figure 2).
For post-ERCP abdominal pain, data were also extracted
from four RCTs [4,7-9]. These trials included 1783
patients with 183 patients suffering from post-ERCP
abdominal pain. Among these patients, 78 patients were
in the gabexate group and 105 patients were in the control
group. The Q test of heterogeneity of effect sizes was sig-
nificant (Q = 9.21, 3 degrees of freedom, p = 0.03).
Although the post-ERCP abdominal pain was noted in
Table 3: Results of the meta-analysis and sensitivity-analysis
Outcome Meta-analysis Sensitivity-analysis I Sensitivity-analysis II
OR P OR P OR P
PEP 0.67 (0.31, 1.47) 0.32 0.99 (0.64, 1.54) 0.97 0.51 (0.17, 1.51) 0.22
Post-ERCP hyperamylasemia 0.88 (0.72, 1.07) 0.20 0.88 (0.70, 1.11) 0.29 0.87 (0.70, 1.09) 0.22
Post-ERCP abdominal pain 0.69 (0.39, 1.21) 0.19 0.86 (0.60, 1.22) 0.39 0.59 (0.28, 1.25) 0.17
Effect of gabexate on the frequency of ERCP-related acute pancreatitis, severe pancreatitis, case-fatality ratio, post-ERCP  hyperamylasemia and post-ERCP abdominal pain Figure 2
Effect of gabexate on the frequency of ERCP-related acute pancreatitis, severe pancreatitis, case-fatality ratio, post-ERCP 
hyperamylasemia and post-ERCP abdominal pain.BMC Gastroenterology 2007, 7:6 http://www.biomedcentral.com/1471-230X/7/6
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8.8% of patients in gabexate group versus 11.7% of
patients in control group, the results of meta-analysis
showed that gabexate treatment in patients of post ERCP
did not release abdominal pain as compared with placebo
control [DL random-effect pooled OR 0.69 (95 percent CI
0.39 to 1.21); p = 0.19] (Figure 2).
Sensitivity-analysis
In addition, we performed the sensitivity-analysis of these
trials because treatment duration was one of the impor-
tant factors that could influence the effectiveness of gabex-
ate. With the sensitivity analysis, we excluded the longest
[4] or the shortest treatment duration [9] separately. We
Sensitivity-analysis II: The study of the shortest treatment duration [9] was excluded Figure 4
Sensitivity-analysis II: The study of the shortest treatment duration [9] was excluded.
Sensitivity-analysis I: The study of the longest treatment duration [4] was excluded Figure 3
Sensitivity-analysis I: The study of the longest treatment duration [4] was excluded.BMC Gastroenterology 2007, 7:6 http://www.biomedcentral.com/1471-230X/7/6
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did not include severe PEP and case-fatality ratio of PEP
because of their limited sample sizes. As shown in Figure
3 and Figure 4, the overall estimates were virtually identi-
cal and the confidence intervals were similar between the
sensitivity-analysis and the meta-analysis (Table 3).
Publication bias
Publication bias was assessed for all pooled ORs with con-
fidence intervals using Begg's test [14,15]. It was shown as
a funnel plot in Figure 5. No evidence of publication bias
was found.
Adverse effect
Adverse effects of gabexate were evaluated in current
study. We found that two reports indicated different
adverse effects of gabexate. In one report, there are 8
patients with adverse effects. Two patients were in gabex-
ate group and six patients in placebo group [4]. Patients in
gabexate group had mild nausea and vomiting in one
case, and self-limiting dyspnea and a hypertensive crisis in
another case. The six patients in the placebo group had
different adverse events: nausea in two, vomiting in three,
hypotension in one, sweating in one, and fatigue in one
case. All these symptoms had been resolved without treat-
ment. In another report from China, common symptoms
such as bloating, nausea, vomiting, or fever were reported
in both groups with no significant difference between
gabexate treatment and placebo groups [7]. Therefore the
authors concluded that there was no significant correla-
tion between the use of gabexate and adverse effects.
Discussion
Acute pancreatitis is the most frequent and serious com-
plication of ERCP, which cannot be always avoided. At
present, searching for drug's prevention of pancreatic
injury after ERCP remains an important issue. Gabexate (a
synthetic protease inhibitor) is able to inhibit the activi-
ties of several proteinases or peptidases such as kallikrein,
trypsin, plasmin, thrombin, phospholipase A2, and C1
esterase. Since the activation of proteinase is one of the
most important pathogeneses in pancreatic injury after
ERCP, several studies have been reported the use of gabex-
ate in post-ERCP for the prevention of pancreatitis. The
first large-scale prospective study was conducted in Italy
and its results were published in 1996 [4]. In this report,
the authors had found that gabexate was able to reduce
pancreatitis after ERCP as compared to the placebo (the
occurrences of PEP were 2% versus 8% respectively).
Moreover, a meta-analysis published in 2000 including
six studies also reported that patients who received gabex-
ate after ERCP had PEP at 1.6% of occurrence rate while
patients in placebo group had PEP at 6.5% [16]. There-
fore, they concluded that gabexate use was associated with
a significant reduction of PEP (p < 0.001). Favourable
conclusions concerning the use of gabexate for the preven-
tion of post-ERCP hyperamylasemia and post-ERCP
abdominal pain were also drawn in this meta-analysis.
Current study had collected four RCTs [4,7-9], which were
published in the world with different languages and we
evaluated the effectiveness and safety of gabexate in the
prophylaxis of post-ERCP pancreatitis. The meta-analysis
showed that the occurrences of PEP [OR = 0.67, 95%CI
(0.31~1.47), p = 0.32], severe PEP [OR = 3.78, 95%CI
(0.62~22.98), p = 0.15], the case-fatality ratio of PEP [OR
= 0.68, 95%CI (0.19~2.43), p = 0.56], post-ERCP hyper-
amylasemia [OR = 0.88, 95%CI (0.72~1.07), p = 0.20],
and post-ERCP abdominal pain [OR = 0.69, 95%CI
(0.39~1.21), p = 0.19] did not correlate with the prophy-
lactic use of gabexate. The results of meta-analysis indi-
cated that gabexate could not prevent pancreatic injury
after ERCP. Moreover, there was no association between
the prophylactic use of gabexate and adverse effects
although it was reported in two RCTs [4,7]. Further evalu-
ation of the safety of gabexate in the prophylaxis of post-
ERCP pancreatitis is required in the future. We had also
evaluated the quality of these RCTs according to the Jadad
score [10], and found that the results of meta-analysis
were consistent with the sensitivity-analysis. However, the
different conclusions between current study and previous
publication [16] could be due to the selection criteria of
inclusion and exclusion. In current study, we only
included randomized controlled clinical trials while the
other included clinical controlled trials and heavily relied
on the conclusion of one clinical controlled trial [4]
because other clinical controlled trials [5,6,17,18] had
very small sample sizes. In addition, a recent meeting
abstract of randomized controlled clinical trial (2006 Ital-
ian Digestive Week) also concluded that gabexate did not
have beneficial effect on the prevention of pancreatic
injury after ERCP [19]. Furthermore, discordance among
the large randomized controlled trials was recognized and
A funnel plot to explore publication bias Figure 5
A funnel plot to explore publication bias.
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ascribed to heterogeneity of patients under study and dif-
ferences in the experimental design [20]. The heterogene-
ity of patients and differences in the experimental design
could explain the divergence of the results such as the
inclusion of high risk patients with PEP [9] versus patients
scheduled to undergo ERCP [4,7,8]. The duration of
gabexate treatment could also contribute the different
outcome, however, in current meta-analysis we did not
include the duration of gabexate treatment in the evalua-
tion. However, it was reported in a recent abstract that up
to 12 hours infusion, gabexate still had no preventive
effect on pancreatic injury after ERCP (2006 Italian Diges-
tive Week).
Conclusion
The present study shows no statistically significant benefit
of prophylactic gabexate use for the prevention of PEP.
Therefore it is not recommended that gabexate should be
used in the prophylaxis of PEP routinely. Moreover it is
clearly indicated that the adverse effect of gabexate after
ERCP is required to be attention.
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